Addex Therapeutics ADXN.SW · CHF

Its shares trade on SIX under the ticker ADXN.SW. It has been listed since 22 May 2007. In the fiscal year to 31 December 2025, it reported revenue of CHF 173,000 and a net loss of CHF 6.7m. At that date it held total assets of CHF 6.4m and shareholders' equity of CHF 4.8m.

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Vincent LawtonIndependent Non-Executive Chairman of the Board of DirectorsCHF 76,857
• Mr. Tim DyerChief Executive Officer, Co-Founder, Member of the Executive Management, DirectorCHF 3.7m
• Dr. Roger MillsMember of the Executive Management, Chief Medical Officer, Member of the Board of Directors, since 2016CHF 27,749
• Dr. Mikhail KalinichevMember of the Executive Management, Head of Translational Science
• Mr. Lenaic TeyssedouMember of the Executive Management, Head of Finance
• Dr. Raymond HillNon-Executive Independent Member of the Board of DirectorsCHF 46,279
• Dr. Isaac MankeNon-Executive Independent Member of the Board of DirectorsCHF 34,597
• Mr. Jake NunnNon-Executive Independent Member of the Board of DirectorsCHF 34,597

Overall

28

Environment

33

Social

14

Governance

38

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.